Acquisition Deadline Looms for HilleVax Shareholders

The future of clinical-stage pharmaceutical company HilleVax will be determined on Monday as the takeover bid from biotechnology specialist XOMA Royalty expires. This pivotal moment forces investors to evaluate what the proposed transaction genuinely offers.

Financial Turnaround Provides Momentum

Recent quarterly figures highlight a significant strategic shift for HilleVax. For the first half of 2025, the company reported a substantially reduced net loss of $11.3 million, a dramatic improvement from the $87.5 million loss recorded during the same period the previous year. This positive change was driven primarily by a steep reduction in research and development expenditures, which fell to $3.3 million from $52.6 million, alongside lower general and administrative costs. With a solid cash position of $159.5 million, the company enters this transaction from a position of financial strength.

Final Hours of Negotiations

XOMA Royalty’s proposal offers shareholders $1.95 per share in cash, plus a contingent value right (CVR). This additional right could yield further payments dependent on several factors: excess liquidity, savings from lease obligations, and potential revenues from the norovirus vaccine program within a five-year period following its regulatory approval. Adding considerable weight to the deal’s prospects, key shareholders—including company executives and directors holding approximately 22.9% of shares—have already pledged their support for the transaction.

Should investors sell immediately? Or is it worth buying Hillevax?

Strategic Reset Following Setbacks

This acquisition represents the concluding chapter in a volatile period for HilleVax. The company began actively seeking strategic alternatives after discontinuing the development of its norovirus vaccine for infants in July 2024 and implementing subsequent workforce reductions. HilleVax’s board of directors unanimously endorsed the deal with XOMA as the most favorable outcome available to all shareholders. The move signals a shift away from in-house drug development toward realizing contingent value from the company’s existing pipeline.

Monday’s Final Decision

Friday’s closing share price of $2.09 rested slightly above the cash offer, indicating market anticipation that the acquisition will be successfully completed. Should a majority of shareholders accept the terms, the deal could be finalized as early as September. For long-term investors who have navigated the company’s various challenges, the offer provides a clear exit strategy. The central question remains: which investors will bank on the future potential payouts from the CVR, and which will opt for the certainty of immediate cash.